ClinicalTrials.gg
TerminatedNCT02842086DISCOVERUpdated Sep 8, 2026Results posted

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

A Phase 3 interventional study of F/TAF and F/TDF in Pre-Exposure Prophylaxis of HIV-1 Infection, sponsored by Gilead Sciences. Terminated at 93 sites in 11 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Following review of accumulated safety data from DISCOVER and real-world use of F/TAF, the sponsor determined that the long-term safety of F/TAF had been demonstrated and no further safety monitoring within the study was required.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,399
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.

02

Conditions studied

  • Pre-Exposure Prophylaxis of HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Must be at high risk of sexual acquisition of
  • HIV-1 negative status
  • MSM and TGW (male at birth) who have at least one of the following:

    • condomless anal intercourse with at least two unique male partners in the past 12 weeks (partners must be either HIV-infected or of unknown HIV status)
    • documented history of syphilis in the past 24 weeks
    • documented history of rectal gonorrhea or chlamydia in the past 24 weeks
  • Adequate renal function: estimated ≥ 60 mL/min according to the formula
  • Adequate liver and hematologic function:

    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 × (ULN) and total ≤ 1.5 mg/dL, or normal direct bilirubin
    • ≥ 1000/mm\^3; ≥ 75,000/mm\^3; ≥ 10 g/dL

Key Exclusion Criteria

  • Grade 3 or Grade 4 proteinuria or glycosuria that is unexplained or not clinically manageable.

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5,399 participants (actual)

Study arms

  • Experimental
    F/TAF

    F/TAF+ F/TDF placebo for at least 96 weeks

    Drug: F/TAF · Drug: F/TDF Placebo

  • Experimental
    F/TDF

    F/TDF+ F/TAF placebo for at least 96 weeks

    Drug: F/TDF · Drug: F/TAF Placebo

  • Experimental
    Open-label

    Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.

    Drug: F/TAF

  • Experimental
    Open-Label Extension

    Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 408 weeks.

    Drug: F/TAF

Interventions

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    200/25 mg tablet administered orally once daily

    Also known as: Descovy®

  • DrugF/TDF

    200/300 mg tablet administered orally once daily

    Also known as: Truvada®

  • DrugF/TAF Placebo

    Tablet administered orally once daily

  • DrugF/TDF Placebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Incidence of HIV-1 Infection Per 100 Person Years (PY)

    The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)

    Time frame: When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)

Secondary outcomes

  1. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase

    Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.

    Time frame: Baseline, Week 48

  2. Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase

    Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.

    Time frame: Baseline, Week 48

  3. Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase

    Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

    Time frame: Baseline, Week 48

  4. Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase

    Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

    Time frame: Baseline, Week 48

  5. Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase

    The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.

    Time frame: Baseline, Week 48

  6. Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase

    Time frame: Baseline, Week 48

  7. Incidence of HIV-1 Infection Per 100 PY

    The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)

    Time frame: When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)

  8. Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase

    Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.

    Time frame: Baseline, Week 96

  9. Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase

    Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.

    Time frame: Baseline, Week 96

  10. Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase

    Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

    Time frame: Baseline, Week 96

  11. Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase

    Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

    Time frame: Baseline, Week 96

  12. Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase

    The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.

    Time frame: Baseline, Week 96

  13. Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase

    Time frame: Baseline, Week 96

  14. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)

  15. Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality

    Time frame: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)

07

Results

Posted Mar 17, 2020

Participant flow

Participants were enrolled at study sites in the United States, Canada, and the European Union. The first participant was screened on 02 September 2016. The data cut date for the end of blinded treatment phase was 12 December 2019.

Participant flow — Overall Study
MilestoneDescovy (DVY)Truvada (TVD)
Started27002699
Completed21562206
Not completed544493
Withdrew: Randomized but never treated66
Withdrew: Still in double-blind phase73
Withdrew: Adverse event1820
Withdrew: Death33
Withdrew: Investigator's discretion913
Withdrew: Non-compliance with study drug98
Withdrew: Protocol violation84
Withdrew: Withdrew consent205194
Withdrew: Lost to follow-up274236
Withdrew: Hiv-1 infection56

Outcome measures

PrimaryIncidence of HIV-1 Infection Per 100 Person Years (PY)

The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)

Time frame:
When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)
Reported as:
Number · HIV-1 infections per 100 PY
Incidence of HIV-1 Infection Per 100 Person Years (PY)
HIV-1 infections per 100 PYDescovy (DVY)Truvada (TVD)
Incidence of HIV-1 Infection Per 100 Person Years (PY)0.160 (0.064 to 0.330)0.342 (0.191 to 0.564)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Rate ratio: 0.468 · 95.003% CI 0.191 to 1.149
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase

Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent Change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase0.218 ± 2.3668-0.968 ± 2.4343
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANOVA · p = <0.0001 · Difference in least squares mean (lsm): 1.142 · 95% CI 0.628 to 1.655
SecondaryPercent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase

Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.

Time frame:
Baseline, Week 48
Reported as:
Mean · Percent Change
Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase0.512 ± 2.9854-1.061 ± 2.9382
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANOVA · p = <0.0001 · Difference in lsm: 1.567 · 95% CI 0.913 to 2.220
SecondaryPercent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase

Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

Time frame:
Baseline, Week 48
Reported as:
Median · Percent Change
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase-10.6 (-42.0 to 25.9)15.4 (-22.9 to 97.2)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Van Elteren test · p = <0.0001 (P-values were from the Van Elteren test stratified by baseline TVD for PrEP.)
SecondaryPercent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase

Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

Time frame:
Baseline, Week 48
Reported as:
Median · Percent Change
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase0.1 (-24.9 to 35.3)20.0 (-13.0 to 68.2)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Van Elteren test · p = <0.0001 (P-values were from the Van Elteren test stratified by baseline TVD for PrEP.)
SecondaryNumber of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase

The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.

Time frame:
Baseline, Week 48
Reported as:
Count of participants · Participants
Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase
ParticipantsDescovy (DVY)Truvada (TVD)
≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 4823182295
≤ 200 mg/g at Baseline; > 200 mg/g at Week 481635
> 200 mg/g at Baseline; ≤ 200 mg/g at Week 48128
> 200 mg/g at Baseline; > 200 mg/g at Week 48910
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Rank analysis of covariance · p = 0.0048 (P-value for difference between treatment groups in distributions of UPCR ≤ 200 mg/g versus \> 200 mg/g was from the rank analysis of covariance adjusting for baseline category and baseline TVD for PrEP.)
SecondaryChange From Baseline in Serum Creatinine at Week 48 in the Blinded Phase
Time frame:
Baseline, Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase
mg/dLDescovy (DVY)Truvada (TVD)
Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase-0.01 ± 0.1070.01 ± 0.111
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANCOVA · p = <0.0001 · Difference in lsm: -0.02 · 95% CI -0.02 to -0.01
SecondaryIncidence of HIV-1 Infection Per 100 PY

The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)

Time frame:
When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)
Reported as:
Number · HIV-1 infections per 100 PY
Incidence of HIV-1 Infection Per 100 PY
HIV-1 infections per 100 PYDescovy (DVY)Truvada (TVD)
Incidence of HIV-1 Infection Per 100 PY0.159 (0.069 to 0.313)0.297 (0.166 to 0.490)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Rate ratio: 0.536 · 95.003% CI 0.227 to 1.264
SecondaryPercent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase

Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.

Time frame:
Baseline, Week 96
Reported as:
Mean · Percent Change
Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase0.565 ± 2.9379-1.048 ± 2.9277
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANOVA · p = <0.0001 · Difference in lsm: 1.567 · 95% CI 0.896 to 2.237
SecondaryPercent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase

Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.

Time frame:
Baseline, Week 96
Reported as:
Mean · Percent Change
Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase0.831 ± 3.4608-1.426 ± 3.5508
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANOVA · p = <0.0001 · Difference in lsm: 2.253 · 95% CI 1.437 to 3.069
SecondaryPercent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase

Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

Time frame:
Baseline, Week 96
Reported as:
Median · Percent Change
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase-14.5 (-45.4 to 23.9)14.1 (-26.2 to 99.5)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Van Elteren test · p = <0.0001 (P-values were from the Van Elteren test stratified by baseline TVD for PrEP.)
SecondaryPercent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase

Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.

Time frame:
Baseline, Week 96
Reported as:
Median · Percent Change
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase
Percent ChangeDescovy (DVY)Truvada (TVD)
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase0.3 (-27.1 to 35.7)21.4 (-13.8 to 73.9)
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Van Elteren test · p = <0.0001 (P-values were from the Van Elteren test stratified by baseline TVD for PrEP.)
SecondaryNumber of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase

The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.

Time frame:
Baseline, Week 96
Reported as:
Count of participants · Participants
Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase
ParticipantsDescovy (DVY)Truvada (TVD)
≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 9621342153
≤ 200 mg/g at Baseline; > 200 mg/g at Week 962128
> 200 mg/g at Baseline; ≤ 200 mg/g at Week 961410
> 200 mg/g at Baseline; > 200 mg/g at Week 9668
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · Rank analysis of covariance · p = 0.2163 (P-value for difference between treatment groups in distributions of UPCR ≤ 200 mg/g versus \> 200 mg/g was from the rank analysis of covariance adjusting for baseline category and baseline TVD for PrEP.)
SecondaryChange From Baseline in Serum Creatinine at Week 96 in the Blinded Phase
Time frame:
Baseline, Week 96
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase
mg/dLDescovy (DVY)Truvada (TVD)
Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase0.01 ± 0.1140.03 ± 0.117
Statistical analysis
  • Descovy (DVY) vs Truvada (TVD) · ANCOVA · p = <0.0001 · Difference in lsm: -0.02 · 95% CI -0.02 to -0.01
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame:
First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsDescovy (DVY)Truvada (TVD)
Percentage of Participants Experiencing Treatment-Emergent Adverse Events93.793.6
SecondaryPercentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
Time frame:
First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
percentage of participantsDescovy (DVY)Truvada (TVD)
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality76.179.1

Adverse events

Collected over First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Descovy (DVY)3/2,694 (0.1%)202/2,694 (7.5%)2,258/2,694 (83.8%)
Truvada (TVD)3/2,693 (0.1%)186/2,693 (6.9%)2,229/2,693 (82.8%)
Most frequent serious events
Showing 10 of 291
Most frequent serious events
EventDescovy (DVY)Truvada (TVD)
AppendicitisInfections and infestations9/269410/2693
Suicidal ideationPsychiatric disorders8/26945/2693
Atrial fibrillationCardiac disorders2/26947/2693
CellulitisInfections and infestations7/26945/2693
Acute kidney injuryRenal and urinary disorders7/26942/2693
Hepatitis AInfections and infestations6/26942/2693
PneumoniaInfections and infestations5/26944/2693
DepressionPsychiatric disorders5/26943/2693
Suicide attemptPsychiatric disorders5/26941/2693
Chest painGeneral disorders2/26944/2693
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDescovy (DVY)Truvada (TVD)
Anal chlamydia infectionInfections and infestations890/2694902/2693
Oropharyngeal gonococcal infectionInfections and infestations871/2694838/2693
Proctitis gonococcalInfections and infestations805/2694797/2693
Exposure to communicable diseaseInjury, poisoning and procedural complications554/2694548/2693
DiarrhoeaGastrointestinal disorders479/2694451/2693
SyphilisInfections and infestations413/2694392/2693
NasopharyngitisInfections and infestations399/2694402/2693
Upper respiratory tract infectionInfections and infestations402/2694346/2693
Urethritis chlamydialInfections and infestations346/2694314/2693
Urethritis gonococcalInfections and infestations259/2694255/2693

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.

Age, Continuous
Age, Continuous(years)Descovy (DVY)Truvada (TVD)Total
Mean36 ± 10.636 ± 10.736 ± 10.6
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Descovy (DVY)Truvada (TVD)Total
Transgender Women452974
Sex: Female, Male
Sex: Female, Male(Participants)Descovy (DVY)Truvada (TVD)Total
Female000
Male269426935387
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Descovy (DVY)Truvada (TVD)Total
Race — American Indian or Alaska Native121426
Race — Asian113120233
Race — Black/Mixed Black240234474
Race — Native Hawaiian or Pacific Islander172340
Race — White226422474511
Race — Other (Nonblack)455095
Race — Not Permitted358
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Descovy (DVY)Truvada (TVD)Total
Ethnicity — Hispanic or Latino6356831318
Ethnicity — Not Hispanic or Latino205820084066
Ethnicity — Not Permitted123
Region of Enrollment
Region of Enrollment(Participants)Descovy (DVY)Truvada (TVD)Total
Canada191162353
Austria354277
Denmark98104202
France181432
Germany187183370
Ireland403878
Italy372158
Netherlands314071
Spain219195414
United Kingdom247265512
United States159116293220
Hip Bone Mineral Density (BMD)
Hip Bone Mineral Density (BMD)(g/cm^2)Descovy (DVY)Truvada (TVD)Total
Mean1.030 ± 0.15531.021 ± 0.13221.025 ± 0.1443
Spine BMD
Spine BMD(g/cm^2)Descovy (DVY)Truvada (TVD)Total
Mean1.134 ± 0.16461.131 ± 0.13811.132 ± 0.1518

4 further baseline measures are reported on the registry.

08

Study locations

93 sites
  • Beverly Hills, California 90211, United States
  • Los Angeles, California 90036, United States
  • Los Angeles, California 90069, United States
  • Newport Beach, California 92663, United States
  • Oakland, California 94609, United States
  • Sacramento, California 95817, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92103, United States
  • San Francisco, California 94102, United States
  • San Francisco, California 94103, United States
  • San Francisco, California 94118, United States
  • Torrance, California 90502, United States
  • Aurora, Colorado 80045, United States
  • Denver, Colorado 80209, United States
  • New Haven, Connecticut 06510, United States
  • Washington D.C., District of Columbia 20009, United States
  • Washington D.C., District of Columbia 20036, United States
  • Fort Lauderdale, Florida 33308, United States
  • Fort Lauderdale, Florida 33316, United States
  • Ft. Pierce, Florida 34982, United States
  • Miami, Florida 33136, United States
  • Orlando, Florida 32803, United States
  • Pensacola, Florida 32504, United States
  • West Palm Beach, Florida 33407, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30309, United States
  • Atlanta, Georgia 30312, United States
  • Macon, Georgia 31201, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60613, United States
  • New Orleans, Louisiana 70119, United States
  • Boston, Massachusetts 02215, United States
  • Springfield, Massachusetts 01105, United States
  • Berkley, Michigan 48072, United States
  • Detroit, Michigan 48202, United States
  • Minneapolis, Minnesota 55415, United States
  • Las Vegas, Nevada 89104, United States
  • Somers Point, New Jersey 08244, United States
  • Santa Fe, New Mexico 87505, United States
  • New York, New York 10029, United States
  • New York, New York 10032, United States
  • New York, New York 10037, United States
  • The Bronx, New York 10467, United States
  • Chapel Hill, North Carolina 27599-7215, United States
  • Huntersville, North Carolina 28078, United States
  • Cleveland, Ohio 44109, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Austin, Texas 78705, United States
  • Dallas, Texas 75208, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77098, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98104, United States
  • Milwaukee, Wisconsin 53226, United States
  • Graz, 8051, Austria
  • Vienna, 1090, Austria
  • Vancouver, British Columbia V6Z 2T1, Canada
  • Toronto, Ontario M5G 1K2, Canada
  • Montreal, Quebec H2l 4P9, Canada
  • Montreal, Quebec H2L5B1, Canada
  • Montreal, Quebec H2W 1T8, Canada
  • Hvidovre, Capital Region 2650, Denmark
  • Aarhus N, Central Jutland 8200, Denmark
  • Copenhagen, RegionH 2100, Denmark
  • Odense, 5000, Denmark
  • Nice, Alpe Maritimes 6202, France
  • Marseille, Provence 13006, France
  • Paris, Provence 75020, France
  • Paris, 75475, France
  • Munich, Bavaria 81675, Germany
  • Berlin, 10439, Germany
  • Berlin, 10777, Germany
  • Frankfurt, 60596, Germany
  • Dublin, Dublin D07 A8NN, Ireland
  • Dublin, 8, Ireland
  • Milan, 20127, Italy
  • Roma, 00149, Italy
  • Amsterdam, Netherlands
  • Badalona, Barcelona 08907, Spain
  • Barcelona, 08015, Spain
  • Madrid, 28010, Spain
  • Vigo, 36312, Spain
  • Soho, London W1D 6AQ, United Kingdom
  • Whitechapel, London E1 1BB, United Kingdom
  • Edinburgh, Scotland EH3 9HA, United Kingdom
  • Brighton, Sussex BN2 1ES, United Kingdom
  • Birmingham, B9 5SS, United Kingdom
  • London, E9 6SR, United Kingdom
  • London, SE18 4QH, United Kingdom
  • London, SE5 9RJ, United Kingdom
  • London, W2 1NY, United Kingdom
  • London, WC1E 6JB, United Kingdom
  • Manchester, M13 0FH, United Kingdom
09

References and documents

Publications

  • Hare B. The Phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV Preexposure Prophylaxis [Presentation]. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 04-07 March; Seattle, WA.
  • Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5. PubMed 32711800 ↗
  • Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial. Lancet HIV. 2024 Aug;11(8):e508-e521. doi: 10.1016/S2352-3018(24)00130-9. Epub 2024 Jul 14. PubMed 39008999 ↗
  • Cespedes MS, Das M, Yager J, Prins M, Krznaric I, de Jong J, Xiao D, Shao Y, Wong P, Kintu A, Carter C, Hoornenborg E, Ruane P, Phoenix J, Younis I, Halperin J. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial. Transgend Health. 2024 Jan 31;9(1):46-52. doi: 10.1089/trgh.2022.0048. eCollection 2024 Feb. PubMed 38312459 ↗
  • Zivich PN, Cole SR, Edwards JK, Glidden DV, Das M, Shook-Sa BE, Shao Y, Mehrotra ML, Adimora AA, Eron JJ. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo. J Infect Dis. 2024 Apr 12;229(4):1123-1130. doi: 10.1093/infdis/jiad507. PubMed 37969014 ↗
  • Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. PubMed 34197772 ↗
  • Glidden DV, Das M, Dunn DT, Ebrahimi R, Zhao Y, Stirrup OT, Baeten JM, Anderson PL. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial. J Int AIDS Soc. 2021 May;24(5):e25744. doi: 10.1002/jia2.25744. PubMed 34021709 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion and at least 6 months after the FDA and EMA approval

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Jan 2019, 28 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 22, 2016
StartActual
Sep 2, 2016
Primary completionActual
Jan 31, 2019
CompletionActual
Jul 29, 2026
Results first posted
Mar 17, 2020
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02842086
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 22, 2016
Start date
Sep 2, 2016
Primary completion
Jan 31, 2019
Completion
Jul 29, 2026
Results posted
Mar 17, 2020
Last update
Sep 8, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide

Start the discussion